AGENT-797

Allogeneic iNKT cell therapy

At AgenTus, we are advancing a pipeline of unique allogeneic cell therapies not only designed to address the limitations of autologous cell therapies but also many of the potential challenges of allogeneic cell therapy approaches currently being pursued.

Our allogeneic iNKTs do not require any genetic manipulation and have been manufactured under GMP conditions and in significantly expanded quantities. Further, if approved they can be offered at a fraction of the cost of existing cell therapies. Our iNKTs can also be used in combination with our own immune checkpoint antibodies as well as with an iNKT cell activating lipid ligand, both designed to improve patient response.

Our world-renowned scientific leadership team includes Dr. Mark Exley, who has over 70 peer-reviewed publications specifically in this field. The advantages of our iNKT platform are summarized in the table below.

The FDA has cleared the IND for AGENT-797.

*CRS: Cytokine Syndrome, which has resulted in life threatening complications with use of first generation cell therapies

^Clinical efficacy unmodified: iNKT have shown to have activity in cancer patients, NK cells can contribute to bone marrow transplant activity with other cells